What is VivoSense?
Founded in 2010, VivoSense specializes in the sophisticated analysis and interpretation of wearable sensor data, a niche that has become increasingly vital for clinical researchers. By leveraging its proprietary VivoSense software, the company creates digital biomarkers that provide rigorous, actionable insights into human physiology. This technology is instrumental in advancing precision medicine and patient-focused drug development across complex therapeutic areas, including oncology, Alzheimer's, and rare diseases. By bridging the gap between raw wearable data and regulatory-grade clinical measures, VivoSense enables pharmaceutical companies to utilize real-world evidence at scale, ultimately streamlining the path to medical decision-making and therapeutic approval.
How much funding has VivoSense raised?
VivoSense has raised a total of $25.1M across 2 funding rounds:
Debt
$150K
Series A
$25M
Debt (2020): $150K with participation from PPP
Series A (2022): $25M led by Debiopharm and Perceptive Xontogeny Venture Fund
Key Investors in VivoSense
Debiopharm
Debiopharm Investment is the strategic investment arm of the Debiopharm Group, focusing on private equity and financial returns to support long-term pharmaceutical innovation.
Perceptive Xontogeny Venture Fund
A specialized venture fund focused on early-stage life sciences and biotechnology companies, providing both capital and operational expertise to accelerate drug development.
PPP
Public-Private Partnership
What's next for VivoSense?
With this major strategic investment, VivoSense is poised to expand its footprint in the global clinical trial market. The company is expected to prioritize the enhancement of its proprietary software platform to support larger, more complex multi-site trials. Furthermore, the capital will likely facilitate deeper integration with regulatory bodies, ensuring that their digital biomarkers become the gold standard for patient monitoring. As the industry shifts toward decentralized clinical trials, VivoSense is well-positioned to capitalize on the demand for remote, body-worn monitoring solutions that maintain scientific rigor while improving patient outcomes. Future growth will likely focus on scaling operations to meet the needs of global pharmaceutical partners seeking to integrate digital endpoints into their core research pipelines.
See full VivoSense company page
